Newborn screening for inborn errors of metabolism

Bridget Wilcken, Piero Rinaldo, Dietrich Matern

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Newborn screening was first applied to the detection of phenylketonuria (PKU) by a bacterial inhibition assay pioneered in 1961 by Guthrie, who was also responsible for the introduction of the use of a dried blood sample [1]. This was followed by further bacterial inhibition assays to detect other aminoacidopathies (maple syrup urine disease, homocystinuria, urea cycle disorders, etc.), but only screening for PKU was widely adopted. In 1975 Dussault described screening for congenital hypothyroidism (CH) [2], and since then other disorders covered in some screening programmes have included congenital adrenal hyperplasia, the galactosaemias, cystic fibrosis, biotinidase deficiency, glucose-6-phosphate dehydrogenase deficiency and many others.

Original languageEnglish (US)
Title of host publicationInborn Metabolic Diseases: Diagnosis and Treatment
PublisherSpringer Berlin Heidelberg
Pages75-86
Number of pages12
ISBN (Print)9783642157202, 9783642157196
DOIs
StatePublished - Jan 1 2012

Fingerprint

Glucosephosphate Dehydrogenase Deficiency
Inborn Errors Metabolism
Phenylketonurias
Biotinidase Deficiency
Inborn Urea Cycle Disorder
Maple Syrup Urine Disease
Homocystinuria
Galactosemias
Congenital Hypothyroidism
Congenital Adrenal Hyperplasia
Cystic Fibrosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wilcken, B., Rinaldo, P., & Matern, D. (2012). Newborn screening for inborn errors of metabolism. In Inborn Metabolic Diseases: Diagnosis and Treatment (pp. 75-86). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-15720-2_3

Newborn screening for inborn errors of metabolism. / Wilcken, Bridget; Rinaldo, Piero; Matern, Dietrich.

Inborn Metabolic Diseases: Diagnosis and Treatment. Springer Berlin Heidelberg, 2012. p. 75-86.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wilcken, B, Rinaldo, P & Matern, D 2012, Newborn screening for inborn errors of metabolism. in Inborn Metabolic Diseases: Diagnosis and Treatment. Springer Berlin Heidelberg, pp. 75-86. https://doi.org/10.1007/978-3-642-15720-2_3
Wilcken B, Rinaldo P, Matern D. Newborn screening for inborn errors of metabolism. In Inborn Metabolic Diseases: Diagnosis and Treatment. Springer Berlin Heidelberg. 2012. p. 75-86 https://doi.org/10.1007/978-3-642-15720-2_3
Wilcken, Bridget ; Rinaldo, Piero ; Matern, Dietrich. / Newborn screening for inborn errors of metabolism. Inborn Metabolic Diseases: Diagnosis and Treatment. Springer Berlin Heidelberg, 2012. pp. 75-86
@inbook{cdac2a398a1b4fe18cfee485beb16b8b,
title = "Newborn screening for inborn errors of metabolism",
abstract = "Newborn screening was first applied to the detection of phenylketonuria (PKU) by a bacterial inhibition assay pioneered in 1961 by Guthrie, who was also responsible for the introduction of the use of a dried blood sample [1]. This was followed by further bacterial inhibition assays to detect other aminoacidopathies (maple syrup urine disease, homocystinuria, urea cycle disorders, etc.), but only screening for PKU was widely adopted. In 1975 Dussault described screening for congenital hypothyroidism (CH) [2], and since then other disorders covered in some screening programmes have included congenital adrenal hyperplasia, the galactosaemias, cystic fibrosis, biotinidase deficiency, glucose-6-phosphate dehydrogenase deficiency and many others.",
author = "Bridget Wilcken and Piero Rinaldo and Dietrich Matern",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-3-642-15720-2_3",
language = "English (US)",
isbn = "9783642157202",
pages = "75--86",
booktitle = "Inborn Metabolic Diseases: Diagnosis and Treatment",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Newborn screening for inborn errors of metabolism

AU - Wilcken, Bridget

AU - Rinaldo, Piero

AU - Matern, Dietrich

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Newborn screening was first applied to the detection of phenylketonuria (PKU) by a bacterial inhibition assay pioneered in 1961 by Guthrie, who was also responsible for the introduction of the use of a dried blood sample [1]. This was followed by further bacterial inhibition assays to detect other aminoacidopathies (maple syrup urine disease, homocystinuria, urea cycle disorders, etc.), but only screening for PKU was widely adopted. In 1975 Dussault described screening for congenital hypothyroidism (CH) [2], and since then other disorders covered in some screening programmes have included congenital adrenal hyperplasia, the galactosaemias, cystic fibrosis, biotinidase deficiency, glucose-6-phosphate dehydrogenase deficiency and many others.

AB - Newborn screening was first applied to the detection of phenylketonuria (PKU) by a bacterial inhibition assay pioneered in 1961 by Guthrie, who was also responsible for the introduction of the use of a dried blood sample [1]. This was followed by further bacterial inhibition assays to detect other aminoacidopathies (maple syrup urine disease, homocystinuria, urea cycle disorders, etc.), but only screening for PKU was widely adopted. In 1975 Dussault described screening for congenital hypothyroidism (CH) [2], and since then other disorders covered in some screening programmes have included congenital adrenal hyperplasia, the galactosaemias, cystic fibrosis, biotinidase deficiency, glucose-6-phosphate dehydrogenase deficiency and many others.

UR - http://www.scopus.com/inward/record.url?scp=84956696001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956696001&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-15720-2_3

DO - 10.1007/978-3-642-15720-2_3

M3 - Chapter

AN - SCOPUS:84956696001

SN - 9783642157202

SN - 9783642157196

SP - 75

EP - 86

BT - Inborn Metabolic Diseases: Diagnosis and Treatment

PB - Springer Berlin Heidelberg

ER -